- Home
- IMCR vs BBAI Comparison
IMCR vs BBAI Comparison
Compare IMCR & BBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- BBAI
- Stock Information
- Founded
- IMCR 2008
- BBAI 2020
- Country
- IMCR United Kingdom
- BBAI United States
- Employees
- IMCR N/A
- BBAI N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- BBAI EDP Services
- Sector
- IMCR Health Care
- BBAI Technology
- Exchange
- IMCR Nasdaq
- BBAI Nasdaq
- Market Cap
- IMCR 1.5B
- BBAI 1.2B
- IPO Year
- IMCR 2021
- BBAI N/A
- Fundamental
- Price
- IMCR $32.77
- BBAI $6.55
- Analyst Decision
- IMCR Buy
- BBAI Strong Buy
- Analyst Count
- IMCR 10
- BBAI 3
- Target Price
- IMCR $58.13
- BBAI $6.17
- AVG Volume (30 Days)
- IMCR 445.1K
- BBAI 176.0M
- Earning Date
- IMCR 08-07-2025
- BBAI 07-31-2025
- Dividend Yield
- IMCR N/A
- BBAI N/A
- EPS Growth
- IMCR N/A
- BBAI N/A
- EPS
- IMCR N/A
- BBAI N/A
- Revenue
- IMCR $333,581,000.00
- BBAI $159,872,000.00
- Revenue This Year
- IMCR $26.82
- BBAI $8.26
- Revenue Next Year
- IMCR $8.15
- BBAI $12.09
- P/E Ratio
- IMCR N/A
- BBAI N/A
- Revenue Growth
- IMCR 25.75
- BBAI 9.40
- 52 Week Low
- IMCR $23.15
- BBAI $1.17
- 52 Week High
- IMCR $41.54
- BBAI $10.36
- Technical
- Relative Strength Index (RSI)
- IMCR 45.73
- BBAI 75.63
- Support Level
- IMCR $30.76
- BBAI $3.78
- Resistance Level
- IMCR $32.55
- BBAI $7.23
- Average True Range (ATR)
- IMCR 1.39
- BBAI 0.56
- MACD
- IMCR -0.41
- BBAI 0.28
- Stochastic Oscillator
- IMCR 19.09
- BBAI 85.66
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About BBAI BigBear.ai Inc.
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment. Company generate revenue by providing customers with Edge AI-powered decision intelligence solutions and services for data ingestion, data enrichment, data processing, artificial intelligence, machine learning, predictive analytics and predictive visualization. It generate revenue from providing both software and services to customers.